test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow classification allows identification of ...

Recombinant monoclonal antibodies (mAbs) are used extensively in modern medicinal approach, for targeting diseases like cancer (trastuzumab for HER2-positive breast cancer ... enzyme-linked ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

The membrane-associated glycoprotein mucin-4 (MUC4) could block inhibitory actions of trastuzumab by directly binding with HER2, preventing interaction between the drug and its molecular target.

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer. HealthDay News — For patients with human epidermal growth factor receptor ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

HER2-low breast cancer falls somewhere in between. Thanks to new targeted treatments, such as a drug called trastuzumab deruxtecan, patients with HER2-low breast cancer now have more options and ...

“The primary analysis of the KATHERINE trial showed that T-DM1, as compared with trastuzumab, improved invasive disease-free survival after neoadjuvant therapy in patients with HER2-positive ...

Trastuzumab rezetecan (SHRA-1811) is under development for the treatment of HER2 expressing or mutated advanced malignant solid tumor, human epidermal growth factor receptor 2 positive breast cancer ...

Datroway is approved for HR-positive, HER2-negative breast cancer after prior endocrine and chemotherapy treatments. TROPION-Breast01 trial showed Datroway improved progression-free survival and ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer. The FDA has approved ...